In:
British Journal of Clinical Pharmacology, Wiley, Vol. 88, No. 4 ( 2022-04), p. 1551-1566
Abstract:
The aim was to perform an umbrella review to summarise the existing evidence on proton‐pump inhibitor (PPI) use and adverse outcomes and to grade the certainty of evidence. Methods Electronic databases were searched up to July 2021 for meta‐analyses of cohort studies and/or randomised controlled trials (RCTs). Summary effect sizes from a random‐effects model, between‐study heterogeneity, 95% prediction interval, small‐study effect, excess significance and credibility ceilings were devised to classify the credibility of evidence from meta‐analyses of cohort studies, whereas the GRADE approach was used for meta‐analyses of RCTs. Results In meta‐analyses of cohort studies, 52 of the 91 examined associations were statistically significant ( P ≤ .05). Convincing evidence emerged from main analysis for the association between PPI use and risk of all‐site fracture and chronic kidney disease in the elderly population. However, none of these associations remained supported by convincing evidence after sensitivity analyses. The use of PPI is also associated with an increased risk of mortality due to COVID‐19 infection and other related adverse outcomes, but the quality of evidence was weak. In meta‐analyses of RCTs, 38 of the 63 examined associations were statistically significant. However, no associations were supported by high or moderate‐quality evidence. Conclusion This study's findings imply that most putative adverse outcomes associated with PPI use may not be supported by high‐quality evidence and are likely to have been affected by underlying confounding factors. Future research is needed to confirm the causal association between PPI use and risk of fracture and chronic kidney disease.
Type of Medium:
Online Resource
ISSN:
0306-5251
,
1365-2125
Language:
English
Publisher:
Wiley
Publication Date:
2022
detail.hit.zdb_id:
1498142-7
SSG:
15,3
Permalink
